公开(公告)号：WO2010138575A1

公开(公告)日：2010-12-02

申请号：PCT/US2010/036184

申请日：2010-05-26

Applicant: ABBOTT LABORATORIES ,  CLARK, Richard, F. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi ,  BELL, Randy, L.

Inventor： CLARK, Richard, F. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi ,  BELL, Randy, L.

IPC: C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D403/14 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D403/14 ,  C07D487/04 ,  C07D513/04

Abstract: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , L 1 , R 2 , R 3 , n, p, Ar 1 , and Ar 2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

Abstract translation: 本文描述了式（I）化合物或其药学上可接受的盐或溶剂合物，其中在说明书中定义了G1，L1，R2，R3，n，p，Ar1和Ar2。 还公开了制备所述化合物的方法，以及包含可用于抑制激酶如IGF-1R的所述化合物的组合物。

公开(公告)号：WO2010138578A1

公开(公告)日：2010-12-02

申请号：PCT/US2010/036187

申请日：2010-05-26

Applicant: ABBOTT LABORATORIES ,  WANG, Gary, T. ,  MANTEI, Robert, A. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  SHEPPARD, George, S. ,  WANG, Jieyi ,  BELL, Randy, L.

Inventor： WANG, Gary, T. ,  MANTEI, Robert, A. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  SHEPPARD, George, S. ,  WANG, Jieyi ,  BELL, Randy, L.

IPC: C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61K31/506 ,  A61K35/00

CPC classification number: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

Abstract translation: 本文描述了式（I）的化合物或其药学上可接受的盐或溶剂合物，其中在说明书中定义了L1，R1，R2，R3，R4，R5和m。 还公开了制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶例如IGF-1R。

公开(公告)号：WO2010138576A1

公开(公告)日：2010-12-02

申请号：PCT/US2010/036185

申请日：2010-05-26

Applicant: ABBOTT LABORATORIES ,  CLARK, Richard, F. ,  BELL, Randy, L. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi

Inventor： CLARK, Richard, F. ,  BELL, Randy, L. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi

IPC: C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , R 2 , R 3 , R 4 , R 5 , n, p, q, Ar 1 , and Ar 2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂化物，其中在说明书中定义了G1，R2，R3，R4，R5，n，p，q，Ar1和Ar2。 本发明还涉及制备所述化合物的方法，以及包含所述化合物的组合物，其可用于抑制诸如IGF-1R的激酶。

公开(公告)号：WO2009134776A2

公开(公告)日：2009-11-05

申请号：PCT/US2009/041945

申请日：2009-04-28

Applicant: ABBOTT LABORATORIES ,  GHAYUR, Tariq ,  MORGAN-LAPPE, Susan, E. ,  REILLY, Edward, B. ,  KINGSBURY, Gillian, A. ,  PHILLIPS, Andrew ,  WANG, Jieyi ,  BELL, Randy, L. ,  NORVELL, Suzanne, M. ,  LI, Yingchun ,  LIU, Junjian ,  YING, Hua

Inventor： GHAYUR, Tariq ,  MORGAN-LAPPE, Susan, E. ,  REILLY, Edward, B. ,  KINGSBURY, Gillian, A. ,  PHILLIPS, Andrew ,  WANG, Jieyi ,  BELL, Randy, L. ,  NORVELL, Suzanne, M. ,  LI, Yingchun ,  LIU, Junjian ,  YING, Hua

IPC: G01N33/53

CPC classification number: C07K16/468 ,  A61K39/39533 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/6872 ,  G01N33/74 ,  G01N2333/515 ,  G01N2333/705 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58 ,  Y10S435/81

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，并且具体涉及它们在疾病的预防，诊断和/或治疗中的用途。

公开(公告)号：WO1996032377A1

公开(公告)日：1996-10-17

申请号：PCT/US1996003907

申请日：1996-03-22

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BROOKS, Clint, D., W. ,  STEWART, Andrew, O. ,  BASHA, Anwer ,  BELL, Randy, L.

IPC: C07C275/64

CPC classification number: C07D409/12 ,  C07C275/64 ,  C07D307/52 ,  C07D333/20 ,  C07D333/58

Abstract: Compounds having the structure of general formula (I) or a pharmaceutically acceptable salt thereof have activity as inhibitors of cyclooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optionally susbtituted carbocyclic aryl, (b) optionally substituted furyl, (c) optionally substituted benzo[b]furyl, (d) optionally substituted thienyl, (e) optionally substituted pyridyloxy, (f) optionally substituted pyridylalkyl, (g) optionally substituted benzo[b]thienyl, (h) optionally substituted pyridyl, (i) optionally substituted quinolyl, and (j) optionally substituted indolyl; X is selected from (a) optionally susbtituted alkyl, (b) optionally substituted alkenyl, and (c) optionally substituted alkynyl; R and R are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z-COOH.

Abstract translation: 具有通式（I）结构的化合物或其药学上可接受的盐具有作为环加氧酶和5-脂氧合酶抑制剂的活性，降低了白三烯B4，C4，D4和E4以及环氧合酶产物如前列腺素和血栓素的生物合成， 可用于治疗炎症和过敏性疾病状态。 化合物具有上述结构，其中A选自（a）任选取代的碳环芳基，（b）任选取代的呋喃基，（c）任选取代的苯并[b]呋喃基，（d）任选取代的噻吩基，（e） 吡啶基氧基，（f）任选取代的吡啶基烷基，（g）任选取代的苯并[b]噻吩基，（h）任选取代的吡啶基，（i）任选取代的喹啉基，和（j）任选取代的吲哚基; X选自（a）任选的取代的烷基，（b）任选取代的烯基，和（c）任选取代的炔基; R 1和R 2独立地选自氢，羟基和烷基; Z为通式Z-COOH的非甾体抗炎药物的残基。

公开(公告)号：EP2435422A1

公开(公告)日：2012-04-04

申请号：EP10726735.3

申请日：2010-05-26

Applicant: Abbott Laboratories

Inventor： WANG, Gary, T. ,  MANTEI, Robert, A. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  SHEPPARD, George, S. ,  WANG, Jieyi ,  BELL, Randy, L.

IPC: C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61K31/506 ,  A61K35/00

CPC classification number: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L
1 , R
1 , R
2 , R
3 , R
4 , R
5 , and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

公开(公告)号：EP2282769A2

公开(公告)日：2011-02-16

申请号：EP09739578.4

申请日：2009-04-28

Applicant: Abbott Laboratories

Inventor： GHAYUR, Tariq ,  MORGAN-LAPPE, Susan, E. ,  REILLY, Edward, B. ,  KINGSBURY, Gillian, A. ,  PHILLIPS, Andrew ,  WANG, Jieyi ,  BELL, Randy, L. ,  NORVELL, Suzanne, M. ,  LI, Yingchun ,  LIU, Junjian ,  YING, Hua

IPC: A61K39/00

CPC classification number: C07K16/468 ,  A61K39/39533 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/6872 ,  G01N33/74 ,  G01N2333/515 ,  G01N2333/705 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58 ,  Y10S435/81

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：EP2435436A1

公开(公告)日：2012-04-04

申请号：EP10727228.8

申请日：2010-05-26

Applicant: Abbott Laboratories

Inventor： CLARK, Richard, F. ,  BELL, Randy, L. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi

IPC: C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G
1 , R
2 , R
3 , R
4 , R
5 , n, p, q, Ar
1 , and Ar
2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物，其中G 1，R 2，R 3，R 4，R 5，n，p，q，Ar 1和Ar 2定义为 说明。 本发明还涉及制备所述化合物的方法，以及包含所述化合物的组合物，其可用于抑制激酶如IGF-1R。

公开(公告)号：EP2435435A1

公开(公告)日：2012-04-04

申请号：EP10727227.0

申请日：2010-05-26

Applicant: Abbott Laboratories

Inventor： CLARK, Richard, F. ,  BA-MAUNG, Nwe, Y. ,  ERICKSON, Scott, A. ,  FIDANZE, Steve, D. ,  MANTEI, Robert, A. ,  SHEPPARD, George, S. ,  SORENSEN, Bryan, K. ,  WANG, Gary, T. ,  WANG, Jieyi ,  BELL, Randy, L.

IPC: C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D403/14 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D403/14 ,  C07D487/04 ,  C07D513/04

Abstract: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G
1 , L
1 , R
2 , R
3 , n, p, Ar
1 , and Ar
2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

Abstract translation: 本文描述了式（I）的化合物或其药学上可接受的盐或溶剂合物，其中G 1，L 1，R 2，R 3，n，p，Ar 1和Ar 2在说明书中定义。 还公开了制备所述化合物的方法和包含所述化合物的组合物，所述组合物可用于抑制激酶如IGF-1R。